Collagen production enhancement and MMP production inhibitor

A composition with leontopodic acid and plant extracts from Asteraceae, Rosaceae, and Saxifragaceae enhances collagen production and inhibits MMP-1, effectively addressing skin sagging and aging by improving skin elasticity and reducing wrinkles.

JP2024163669APending Publication Date: 2024-11-22POLA CHEMICAL INDUSTRIES INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2023079484
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing skincare solutions fail to effectively enhance collagen production and suppress matrix metalloprotease (MMP) production, leading to issues such as skin sagging and aging.

Method used

A composition containing leontopodic acid, leontopodic acid-containing extracts, and plant extracts from Asteraceae, Rosaceae, Amygdaloideae, and Saxifragaceae, particularly from the genus Hydrangea, is used to promote type I collagen production and inhibit MMP-1, addressing skin aging and sagging.

Benefits of technology

The composition enhances collagen production, suppresses MMP-1 activity, thereby improving skin elasticity and reducing the appearance of sagging and wrinkles, providing a lifting effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163669000007
    Figure 2024163669000007
  • Figure 2024163669000008
    Figure 2024163669000008
  • Figure 2024163669000009
    Figure 2024163669000009
Patent Text Reader

Abstract

To provide a novel composition that enhances collagen production and inhibits MMP production.SOLUTION: The present invention provides an agent that enhances collagen production and inhibits MMP (matrix metalloprotease) production, the agent containing, as an active ingredient, one or more selected from leontopodic acid, leontopodic acid-containing extracts, and extracts derived from one or more plants of the genus Artemisia (family Asteraceae), genus Amygdaloideae (family Rosaceae), or genus Hydrangea (family Saxifragaceae).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an agent for enhancing collagen production and suppressing MMP production. [Background technology]

[0002] As we age, various aging phenomena such as age spots, wrinkles, and sagging skin appear on the human skin. Research is ongoing to find ingredients that can improve or inhibit these aging phenomena.

[0003] As a conventional technique, for example, it is known that edelweiss extract has an excellent active oxygen scavenging effect and can effectively improve or prevent skin aging and pigmentation (Patent Document 1). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2001-288032 A Summary of the Invention [Problem to be solved by the invention]

[0005] In view of the above-mentioned prior art, an objective of the present invention is to provide a novel composition that enhances collagen production and inhibits MMP production. In addition, in a preferred embodiment of the present invention, it is an object of the present invention to provide a novel composition that has any one of the following effects: preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face, lifting the skin, or lifting the skin. [Means for solving the problem]

[0006] The present invention, which solves the above problems, provides an agent for enhancing collagen production and inhibiting MMP (matrix metalloproteinase) production, which contains one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae. The present invention, which contains the above-mentioned active ingredient, can enhance collagen production and inhibit MMP production in cells, tissues, etc.

[0007] In a preferred embodiment of the invention, the collagen is type I collagen. In a preferred embodiment of the invention, said MMP (matrix metalloprotease) is MMP-1. The present invention containing the above-mentioned active ingredient can enhance the production of type I collagen and inhibit the production of MMP-1 in cells, tissues, etc.

[0008] In a preferred embodiment of the present invention, the agent according to the present invention is used for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face.

[0009] In a preferred embodiment of the present invention, the agent according to the present invention is used for lifting the skin.

[0010] In a preferred embodiment of the present invention, the agent according to the present invention is used for lifting the skin.

[0011] In a preferred embodiment of the present invention, the plant extract is one or more selected from the group consisting of mugwort extract, peach leaf extract, and amacha extract.

[0012] In a preferred embodiment of the invention, the leontopodic acid is leontopodic acid A and / or leontopodic acid B.

[0013] The present invention also relates to a composition for external application to the skin for enhancing collagen production and suppressing MMP (matrix metalloproteinase) production, which contains one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and plant extracts of one or more plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae.

[0014] In a preferred embodiment of the present invention, the composition for external application to skin according to the present invention is a cosmetic preparation.

[0015] In a preferred embodiment of the present invention, the topical skin composition of the present invention is applied to both the left and right cheeks under the same conditions. By applying the skin topical composition of the present invention to both the left and right cheeks under the same conditions, the skin can be lifted more reliably.

[0016] The present invention also relates to an external skin composition for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face, which contains as an active ingredient one or more selected from leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae.

[0017] The present invention also relates to a lifting agent containing, as an active ingredient, one or more selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae.

[0018] The present invention also relates to an external skin composition for lifting the skin, comprising one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae.

[0019] The present invention also relates to an external skin composition for lifting the skin, comprising one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae.

[0020] Furthermore, the present invention also relates to a method for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face (excluding medical procedures), which comprises applying to the left and right cheeks under the same conditions an external skin composition containing one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae.

[0021] Furthermore, the present invention also relates to a method for lifting the skin (excluding medical procedures), which comprises applying a composition for external use on the skin containing one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae to the left and right cheeks under the same conditions. Effect of the Invention

[0022] According to the present invention, a novel composition that enhances collagen production and inhibits MMP production can be provided. [Brief description of the drawings]

[0023] [Figure 1] FIG. 1 is a graph showing the expression levels of COL1A1 gene by leontopodic acids A and B in <Test Example 1>. [Diagram 2] FIG. 1 is a graph showing the expression levels of MMP1 gene by leontopodic acids A and B in <Test Example 1>. [Diagram 3] <Test Example 5-1> Regarding the left-right symmetry of cheek volume, this is a diagram showing the left-right difference in the amount of change in cheek volume before and after continuous use in the "changed" and "no change" groups. [Figure 4] <Test Example 5-2> Regarding the evaluation of anisotropy of cheek skin surface morphology, this is a diagram showing the measurement results of the anisotropy of cheek skin surface morphology before and after continuous use in the "changed" group. [Diagram 5] <Test Example 5-2> FIG. 13 is a diagram showing the tendency of change in anisotropy of cheek skin surface morphology for the "changed" and "no change" groups with respect to the evaluation of anisotropy of cheek skin surface morphology. [Figure 6] <Test Example 5-3> A diagram showing the number of outward and upward arrows per unit area in the lower cheek for the "changed" and "no change" groups, regarding the evaluation of the movement pattern of the cheek skin surface. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] <Collagen production enhancer and MMP (matrix metalloproteinase) production inhibitor> First, the collagen production enhancer and MMP (matrix metalloproteinase) production inhibitor of the present invention will be described in detail.

[0025] <Active ingredients> The collagen production enhancer and MMP (matrix metalloproteinase, hereinafter simply referred to as MMP) production inhibitor of the present invention contains as an active ingredient one or more selected from leontopodic acid, an extract containing leontopodic acid, and plant extracts of one or more plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloideae of the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae (hereinafter simply referred to as Artemisia of the family Asteraceae, Amygdaloideae of the family Rosaceae, and Hydrangea of ​​the family Saxifragaceae). More preferred forms of the active ingredient according to the present invention will be described in detail below.

[0026] [Leontopodic acid] In the present invention, leontopodic acid can be used as an active ingredient. Here, in the present invention, Leontopodic acid is a compound having the basic skeleton of Leontopodic acid, and includes analogues within the range that exhibit the uses of the present invention (such as the effects of enhancing collagen production and inhibiting MMP production). Here, preferred examples of leontopodic acid include leontopodic acid A and leontopodic acid B.

[0027] Here, leontopodic acid A and leontopodic acid B are compounds represented by the following structural formulas (1) and (2).

[0028] [ka]

[0029] [ka]

[0030] In the present invention, it is particularly preferable to use leontopodic acid A as an active ingredient.

[0031] Here, leontopodic acid can be obtained by isolating it from edelweiss extract by HPLC chromatography. Leontopodine acid can also be obtained by purchasing it from EXTRASYNTHESE.

[0032] [Leontopodic acid-containing extract] In the present invention, a leontopodic acid-containing extract can be used as an active ingredient. Here, the leontopodic acid-containing extract according to the present invention is preferably a plant extract. For example, an extract containing leontopodine acid is edelweiss extract.

[0033] Edelweiss extract can be obtained by crushing and extracting the above-ground parts of edelweiss (Leontopodium alpinum). A preferred example of an extraction solvent for obtaining edelweiss extract is 70% ethanol. In addition, the edelweiss extract is preferably one obtained by extracting edelweiss (Leontopodium alpinum), removing ethanol, and adding glycerin.

[0034] However, the leontopodic acid-containing extract of the present invention is not particularly limited to the part of the plant that can be extracted or the extraction method, so long as it contains leontopodic acid and is capable of exerting the uses of the present invention (such as enhancing collagen production and inhibiting MMP production).

[0035] [Plant extract] In the present invention, one or more plant extracts belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae can be used as active ingredients. In the present invention, the above plant extracts can also be used in combination, more preferably two or more, more preferably three or more.

[0036] Here, as a plant of the genus Artemisia in the family Asteraceae, mugwort (Artemisia princeps Pampanini) can be preferably mentioned. Furthermore, as a plant of the genus Prunus in the family Rosaceae, peach (Prunus persica Batsch) can be preferably mentioned. Furthermore, as a plant belonging to the genus Hydrangea in the family Saxifragaceae, a preferred example is Hydrangea serrata Seringe var. thunbergii Sugimoto. Hereinafter, in this specification, they will be referred to simply as mugwort, peach, and amacha, respectively.

[0037] The plant extract used in the present invention can be extracted using the whole plant, or the plant body, above-ground parts, roots and stems, trunks, leaves, stems, spikes, flower buds, etc., but it is preferable to crush or chop them in advance to improve the extraction efficiency. Suitable examples of the extraction solvent include one or more polar solvents selected from water, alcohols such as ethanol, isopropyl alcohol, butanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, ketones such as acetone, methyl ethyl ketone, ethers such as diethyl ether, tetrahydrofuran, etc. The extraction solvent is preferably water, alcohols, or a mixture of water and alcohols.

[0038] Specific extraction methods include, for example, a method in which 1 to 30 parts by mass of a solvent is added per 1 mass of the part of the plant body or the dried part used for extraction, followed by immersion for several days at room temperature or several hours at a temperature near the boiling point, and then cooling to room temperature, after which insoluble matter and / or the solvent are removed as desired, and fractionation and purification is performed by column chromatography or the like, but the extraction method is not limited to this.

[0039] Next, the plant extract used in the present invention will be described in detail.

[0040] When obtaining a plant extract from a plant belonging to the genus Artemisia of the family Asteraceae, it is preferable to obtain the plant extract from Artemisia leaves. When obtaining a plant extract from a plant belonging to the genus Artemisia of the family Asteraceae, it is preferable to use water, ethanol, propylene glycol, 1,3-butylene glycol, or a mixture thereof as an extraction solvent. In addition, commercially available products can be used as the plant extract of a plant belonging to the genus Artemisia of the family Asteraceae.

[0041] When obtaining a plant extract from a plant belonging to the genus Hydrangea of ​​the family Saxifragaceae, it is preferable to obtain the plant extract from the leaves and branch tips of Hydrangea officinalis. When obtaining a plant extract from a plant belonging to the genus Hydrangea of ​​the family Saxifragaceae, it is preferable to use water, ethanol or a mixture thereof as an extraction solvent. In addition, commercially available products can be used as the plant extract of a plant belonging to the genus Hydrangea of ​​the family Saxifragaceae.

[0042] When obtaining a plant extract from a plant of the genus Peach in the family Rosaceae, it is preferable to obtain the plant extract from peach leaves. Also, when obtaining a plant extract from a plant of the genus Peach in the family Rosaceae, it is preferable to use water, ethanol, propylene glycol, 1,3-butylene glycol, or a mixture thereof, or absolute ethanol as an extraction solvent. In addition, commercially available products can be used as the plant extract of a plant belonging to the genus Peach in the family Rosaceae.

[0043] ≪Applications≫ The above-mentioned active ingredients can be used to enhance collagen production and inhibit MMP production. That is, the present invention can be in the form of an agent for enhancing collagen production and suppressing MMP production, comprising the above-mentioned active ingredient.

[0044] Here, preferably, the collagen is type I collagen, and the MMP is MMP-1.

[0045] Type I collagen is abundant in the dermis of the skin and provides strength and elasticity to the skin. The COL1A1 gene plays an important role in the production of type I collagen, which is composed of two α1 chains encoded by the COL1A1 gene and one α2 chain encoded by the COL1A2 gene. MMP-1 can also degrade type I collagen. Therefore, by suppressing the production of MMP-1 in combination with enhancing the production of type I collagen, the effects of the present invention can be exerted more efficiently. In addition, it is believed that skin aging is related to the decreased expression of the COL1A1 gene and the increased expression of the MMP1 gene. Therefore, from the perspective of preventing skin aging, it is extremely important to inhibit the production of MMP-1 in addition to increasing the production of type I collagen.

[0046] Here, the method for detecting whether or not the production of type I collagen in cells is enhanced is not particularly limited, and any method that can be appropriately selected by a person skilled in the art can be used. Furthermore, the method for detecting whether or not the production of MMP-1 in cells is suppressed is not particularly limited, and any method that can be appropriately selected by a person skilled in the art can be used.

[0047] As will be shown in the examples below, the collagen production enhancer and MMP production inhibitor of the present invention can be used to prevent or improve the impression of aging caused by changes in the three-dimensional shape of the face.

[0048] In the present invention, "the impression of aging due to changes in the three-dimensional shape of the face" means that the facial skin gives the impression of sagging, making the face look older. The change in the three-dimensional shape of the face may be the degree of cheek fullness, downward movement of the skin, a change in the skin surface shape, etc. The change in the three-dimensional shape of the face is preferably a change in the three-dimensional shape of the cheeks. The presence or absence and degree of apparent aging can be judged by visual inspection. Changes in the three-dimensional shape of the face can be evaluated by visual inspection, facial image data, three-dimensional facial shape data, etc.

[0049] In the present invention, when referring to the impression aging caused by the change in the three-dimensional shape of the face, "prevention or improvement" refers to not causing impression aging, reducing the risk of occurrence, causing impression aging but suppressing its degree (suppression), and causing impression aging but maintaining its degree or suppressing its progression degree (suppression), unless otherwise specified.Whether impression aging is prevented or improved can be evaluated by a person skilled in the art using an appropriate method and appropriate criteria.

[0050] Furthermore, the collagen production enhancer and MMP production inhibitor of the present invention can be used for skin lifting purposes.

[0051] In the present invention, "lifting the skin" means lifting upward skin that has lost its firmness or that has lost its firmness and become saggy.

[0052] Furthermore, the collagen production enhancer and MMP production inhibitor of the present invention can be used for skin lifting purposes. Therefore, the present invention also relates to a skin lifting agent.

[0053] In the present invention, "skin lifting" refers to the impression that the skin is lifted. Factors that give the impression of lifted skin include a change in the three-dimensional shape of the face, an upward movement of the skin, and an improvement in the surface shape of the cheek skin. In the present invention, the skin is preferably facial skin, more preferably cheek skin.

[0054] In the present invention, in order to be said to have the effect of "lifting the skin," it includes not only the skin being lifted, but also one or more of the following: improving the symmetry of the cheek volume, reducing the anisotropy of the cheek skin surface morphology, and causing the cheek skin surface to move outward and upward. Here, in order for the present invention to be said to have the effect of "lifting the skin," it is preferable for two or more, and more preferably all, of the following changes to be observed: improved symmetry of cheek volume, reduced anisotropy of the cheek skin surface morphology, and an outward and upward movement pattern of the cheek skin surface.

[0055] In the present invention, the term "cheek volume" refers to the degree of cheek fullness. Preferably, it refers to the degree of cheek fullness toward the front as viewed from a horizontal cross section of the cheek in the direction horizontal to the face. More preferably, it refers to the degree of cheek fullness toward the front as viewed from a cross section of the cheek in Camper's plane.

[0056] Methods for measuring cheek volume include direct visual measurement of the face, visual measurement from facial image data, measurement from a heat map of the luminance distribution of the face (hereinafter referred to as a luminance distribution heat map), measurement from three-dimensional shape data of the face, etc. When measuring the sense of cheek volume from a luminance distribution heat map, it is preferable to measure the area of ​​the highest point of the cheek. When measuring cheek volume from three-dimensional facial shape data, it is preferable to measure the cheek volume using a VECTRA M3 (Canfield, Inc.) etc. It is also more preferable to obtain a Camper's plane cross-section of the cheek and measure the degree of forward cheek bulge.

[0057] In the present invention, the "symmetry of cheek volume" refers to the degree of difference between the left and right cheeks in bulging. Preferably, it refers to the degree of difference between the left and right cheeks in bulging when viewed from a horizontal cross section of the cheeks in the horizontal direction relative to the face. More preferably, it refers to the degree of difference between the left and right cheeks in bulging when viewed from a cross section of the cheeks in Camper's plane.

[0058] In the present invention, the "cheek skin surface morphology" refers to the unevenness of the skin surface, including skin texture, wrinkles, and pores. Furthermore, the cheek skin surface morphology refers to the skin surface morphology of the entire cheek, and more preferably, the skin surface morphology of the upper cheek.

[0059] In the present invention, the "anisotropy of the cheek skin surface morphology" means the uniformity of the cheek skin surface morphology. Furthermore, in the present invention, "the anisotropy of the cheek skin surface morphology is low" means that the cheek skin surface morphology is uniform and the directionality of flow in a certain direction (directivity of the cheek skin surface morphology) is small.

[0060] The anisotropy of the cheek skin surface morphology can be measured using facial image data or three-dimensional facial shape data, etc. Preferably, PRIMOS_CR_LargeField (Canfield Scientific) or the like is used.

[0061] In the present invention, the "movement pattern of the cheek skin surface" refers to the manner in which the skin moves. For example, it refers to the downward movement of the skin due to a change in the skin surface morphology, or the upward movement of the skin due to improved skin firmness. Here, "the movement pattern of the cheek skin surface is outward and upward" means that the change in the skin surface shape is perpendicular to the midline of the face, away from the midline of the face (outward movement pattern), and toward the head (upward movement pattern).

[0062] Methods for measuring the movement pattern of the cheek skin surface include measurements from facial image data or three-dimensional facial shape data. When measuring the movement pattern of the skin from facial image data, optical flow analysis in MATLAB (registered trademark) (manufactured by MathWorks) can be used. Specifically, by acquiring the amount of change over time in the position information of feature points (for example, moles, blemishes, and pores) in the facial image data, the movement pattern of the skin can be measured from the facial image data.

[0063] ≪Dosage / Dosage≫ The collagen production enhancer and MMP production inhibitor of the present invention can be administered to mammals including humans. The preferred administration route is parenteral administration, and more preferably application to the skin.

[0064] When the collagen production enhancer and MMP production inhibitor of the present invention is applied to the face, it is preferable to apply it to both the left and right cheeks under the same conditions. Here, "the same conditions" means that one or more of the amount, number of times, timing, and application method are substantially the same. In the present invention, it is preferable that the amount, number of times, timing, and application method are the same for two or more conditions, more preferably three or more conditions, and further preferably all conditions are the same.

[0065] The collagen production enhancer and MMP production inhibitor of the present invention can be administered to mammals, including humans, once a week or several times a week. Furthermore, the collagen production enhancer and MMP production inhibitor of the present invention is preferably administered to mammals, including humans, in a continuous manner.

[0066] When the collagen production enhancer and MMP production inhibitor of the present invention is applied continuously, the application period is preferably 2 weeks or more, more preferably 3 weeks or more, and even more preferably 4 weeks or more. Furthermore, when the collagen production enhancing and MMP production inhibitor of the present invention is applied continuously for the above-mentioned period, the frequency of application can be at least once a week, preferably at least twice a week, more preferably at least once a day, and even more preferably at least twice a day.

[0067] <Skin external composition> <Active ingredients> The topical skin composition of the present invention contains as an active ingredient one or more selected from leontopodic acid, an extract containing leontopodic acid, and plant extracts of one or more plants belonging to the genus Artemisia of the Asteraceae family, the genus Prunus of the Rosaceae family, and the genus Hydrangea of ​​the Saxifragaceae family. Here, the above explanation can be applied to preferred embodiments of the active ingredient in the composition for external use on skin of the present invention. The uses of the topical skin composition of the present invention will be described in more detail below.

[0068] ≪Applications≫ The composition for external use on the skin according to the present invention can be used for enhancing collagen production and suppressing MMP production, as shown in the examples described later. That is, the present invention can be in the form of an external skin composition for enhancing collagen production and suppressing MMP production.

[0069] As shown in the examples below, the composition for external use on the skin according to the present invention can be used to prevent or improve the impression of aging caused by changes in the three-dimensional shape of the face. That is, the present invention can be in the form of an external skin composition for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face.

[0070] Furthermore, the composition for external use on the skin according to the present invention can be used for lifting the skin, as shown in the examples described later. That is, the present invention can be in the form of an external skin composition for skin lifting.

[0071] The composition for external use on the skin according to the present invention can be used for skin lifting purposes, as shown in the examples described later. That is, the present invention can be in the form of an external skin composition for skin lifting. Here, the terms relating to the uses are those explained in the section on the agent according to the present invention.

[0072] ≪Dosage / Dosage≫ The dosage regime for the topical skin composition of the present invention partially overlaps with the dosage regime described in the section on the agent of the present invention. Therefore, the detailed explanation partially incorporates the contents described in the section on uses of the agent of the present invention, and additional explanations are provided below in detail.

[0073] The content of leontopodine acid in the composition for external skin application is 0.00000001% by mass or more, preferably 0.0000001% by mass or more, more preferably 0.000001% by mass or more, and even more preferably 0.000005% by mass or more. The content of leontopodic acid in the composition for external skin application is 30% by mass or less, preferably 15% by mass or less, and more preferably 10% by mass or less.

[0074] The content of the leontopodine acid-containing extract and the plant extract in the topical skin composition is, based on the dry mass, 0.0000001 mass% or more, preferably 0.000001 mass% or more, more preferably 0.00001 mass% or more, even more preferably 0.0001 mass% or more, and even more preferably 0.001 mass% or more. In addition, the content of the leontopodine acid-containing extract and the plant extract in the composition for external use on skin is 80% by mass or less, preferably 30% by mass or less, and more preferably 10% by mass or less.

[0075] Suitable examples of skin external compositions include cosmetics, quasi-drugs, and medicines, with cosmetics and quasi-drugs being more preferred since they can be used on a daily basis. The cosmetic of the present invention can be processed into the form of a lotion, emulsion, gel, cream, ointment, etc. Specific examples include lotion, milky lotion, cream, gel, pack, beauty essence, hair cream, spray, sun care product, rinse-off product such as face wash, etc., and particularly preferred examples include lotion, milky lotion and cream.

[0076] When the present invention is in the form of a cosmetic preparation, ingredients that are usually used in cosmetics may be blended as optional ingredients in addition to the whitening ingredient, wrinkle improving ingredient, anti-inflammatory ingredient, moisturizing ingredient, and active ingredient, as long as the use of the present invention is not impaired. These optional ingredients may be commercially available and used, or may be synthesized by a known method and used. Each optional ingredient may have two or more effects (for example, a whitening effect and an anti-wrinkle effect).

[0077] The whitening ingredient may be any ingredient commonly used in cosmetics, without any particular limitations. Examples of the whitening ingredient include 4-n-butylresorcinol, ascorbic acid glucoside, 3-O-ethyl ascorbic acid, tranexamic acid, arbutin, 1-triphenylmethylpiperidine, 1-triphenylmethylpyrrolidine, 2-(triphenylmethyloxy)ethanol, 2-(triphenylmethylamino)ethanol, 2-(triphenylmethyloxy)ethylamine, triphenylmethylamine, triphenylmethanol, triphenylmethane and aminodiphenylmethane, N-(o-toluoyl)cysteic acid, N-(m-toluoyl)cysteic acid, N-(p-toluyl)cysteic acid, N-(p-methoxybenzoyl)cysteic acid, N-benzoyl-serine, N-(p-methyl Benzoyl)serine, N-(p-ethylbenzoyl)serine, N-(p-methoxybenzoyl)serine, N-(p-fluorobenzoyl)serine, N-(p-trifluoromethylbenzoyl)serine, N-(2-naphthoyl)serine, N-(4-phenylbenzoyl)serine, N-(p-methylbenzoyl)serine methyl ester, N-(p-methylbenzoyl)serine ethyl ester, N-(2-naphthoyl)serine methyl ester, N-benzoyl-O-methylserine, N-(p-methylbenzoyl)-O-methylserine, N-(p-methylbenzoyl)-O-acetylserine, N-(2-naphthoyl)-O-methylserine, dexpanthenol W, niacinamide, and the like can be mentioned.

[0078] The content of the whitening ingredient in the cosmetic is usually 0.0001 to 30% by mass, preferably 0.001 to 10% by mass, and more preferably 0.01 to 5% by mass.

[0079] As the wrinkle-improving component, any component generally used in cosmetics can be used without any particular limitation. For example, wrinkle improving ingredients include vitamin A or its derivatives such as retinol, retinal, retinoic acid, tretinoin, isotretinoin, tocopherol retinoate, retinol palmitate, and retinol acetate.Furthermore, examples include ursolic acid benzyl ester, ursolic acid phosphate, betulinic acid benzyl ester, benzilic acid phosphate, trifluoroisopropyloxopropylaminocarbonylpyrrolidinecarbonylmethylpropylaminocarbonylbenzoylamino sodium acetate, and niacinamide.

[0080] The content of the wrinkle-soothing ingredient in the cosmetic preparation is usually 0.0001 to 30% by mass, preferably 0.001 to 10% by mass, and more preferably 0.01 to 5% by mass.

[0081] Anti-inflammatory ingredients include, for example, clarinone, glabridin, glycyrrhizinic acid, glycyrrhetinic acid, pantothenyl alcohol, niacinamide, tranexamic acid, and the like, and preferred examples include glycyrrhizinic acid and its salts, alkyl glycyrrhetinates and their salts, and glycyrrhetinic acid and its salts.

[0082] The content of the anti-inflammatory component in the cosmetic is usually 0.01 to 30% by mass, preferably 0.1 to 10% by mass, and more preferably 1 to 5% by mass (dry mass in the case of an extract).

[0083] Moisturizing ingredients include sodium pyrrolidone carboxylate, lactic acid, sodium lactate, tetradecylaminobutyroylvalylaminobutyric acid urea trifluoroacetate, and the like.

[0084] The content of the moisturizing ingredient in the cosmetic preparation is usually from 0.0001 to 30% by mass, preferably from 0.001 to 10% by mass, and more preferably from 0.01 to 5% by mass.

[0085] In addition to the active ingredients, other ingredients commonly used in cosmetics include polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, lutitol, propylene glycol, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexylene glycol, 1,2-hexanediol, 1,2-octanediol and other polyols, fatty acid soaps (sodium laurate, sodium palmitate, etc.), potassium lauryl sulfate, and triethanolamine ether alkyl sulfate. anionic surfactants such as stearyl trimethylammonium chloride, benzalkonium chloride, laurylamine oxide, cationic surfactants such as stearyl trimethylammonium chloride, benzalkonium chloride, laurylamine oxide, imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine-based surfactants (alkyl betaine, amido betaine, sulfo betaine, etc.), acyl methyl taurine, and other amphoteric surfactants, sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (monostearyl glycerin phosphate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ether, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbit fatty acid esters (POE-sorbitan monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), P OE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl ether, etc.), Pluronic (registered trademark) types, POE·POP alkyl ethers (POE·POP 2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, nonionic surfactants such as alkyl glucosides, which may be surface-treated, mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate,powders such as silicic anhydride (silica), aluminum oxide, barium sulfate, etc.; inorganic pigments such as cobalt oxide, ultramarine, Prussian blue, zinc oxide, etc., which may be surface-treated; composite pigments such as sintered iron oxide titanium dioxide, etc., which may be surface-treated; pearling agents such as titanium mica, fish phosphorus foil, bismuth oxychloride, etc., which may be surface-treated; organic dyes such as Red No. 202, Red No. 228, Red No. 226, Yellow No. 4, Blue No. 404, Yellow No. 5, Red No. 505, Red No. 230, Red No. 223, Orange No. 201, Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, Red No. 204, etc., which may be laked; Examples of suitable vitamins include organic powders such as polyethylene powder, polymethylmethacrylate, nylon powder, and organopolysiloxane elastomers; lower alcohols such as ethanol and isopropanol; vitamin A or a derivative thereof; vitamin B such as vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or a derivative thereof, vitamin B12, and vitamin B15 or a derivative thereof; vitamin E such as α-tocopherol, β-tocopherol, γ-tocopherol, and vitamin E acetate; and vitamins D, vitamin H, pantothenic acid, pantethine, and pyrroloquinoline quinone.

[0086] It is also preferable that the present invention be in a form labeled with an indication of its intended use, such as "for preventing or improving the appearance of aging due to changes in the three-dimensional shape of the face," "for lifting the skin," or "for lifting the skin."

[0087] The above-mentioned "representation" includes all representations that have the function of informing consumers of the above-mentioned uses. In other words, any representation that can recall or infer the above-mentioned uses falls under the above-mentioned "representation", regardless of the purpose of the representation, the content of the representation, the object or medium on which it is displayed, etc. In addition, the phrase "labeled" means that there is a labeling action intended to cause the viewer to associate the label with a skin topical agent, etc. (product).

[0088] The act of displaying the intended use is preferably one that enables consumers to directly recognize the intended use.Specific examples include the act of describing the intended use on the product or its packaging according to the present invention, and the act of describing the intended use in advertisements for the product, price lists, or transaction documents (including those provided by electromagnetic means).

[0089] <Method for preventing or improving the appearance of aging caused by changes in facial three-dimensional shape and method for lifting the skin> Next, a method for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face and a method for lifting the skin will be described in detail.

[0090] In a preferred embodiment of the present invention, the composition for external use on the skin according to the present invention is used during normal skin care. Preferably, the skin topical composition of the present invention is applied to both cheeks under the same conditions. The application can be performed by taking an amount to be used on the palm of the hand and spreading it over the entire palm of both hands. Next, the skin topical composition is applied to the entire face, preferably to the chin, cheeks, forehead, and face line, as if wrapping the face with the entire palm of the hand. For small areas (eyes, nose, mouth), fingertips can be used. More preferably, the composition is applied to the skin in an upward, lifting manner.

[0091] When the topical composition for skin according to the present invention is applied to the skin using a sheet mask or pack, it is preferable to impregnate a nonwoven fabric or the like with the topical composition for skin according to the present invention and apply it to the skin.

[0092] The method of the present invention can be carried out by a user, manufacturer, distributor, makeup artist, beauty staff, esthetician, or the like of the topical skin composition of the present invention.

[0093] Here, the cosmetic method according to the present embodiment does not include medical treatment. Furthermore, the cosmetic method according to the present invention is a non-therapeutic method.

[0094] The present invention will be described in more detail below with reference to examples, but it goes without saying that the present invention is not limited to these examples.

[0095] In the examples, mugwort extract, peach leaf extract and hydrangea extract were used as plant extracts of plants belonging to the genus Artemisia of the Asteraceae family, the genus Prunus of the Rosaceae family and the genus Hydrangea of ​​the Saxifragaceae family, but the present invention is not limited thereto. EXAMPLES

[0096] <Test Example 1> Collagen production enhancement and MMP production inhibition test of Leontopodic Acids A and B First, leontopodic acids A and B were evaluated for their collagen production enhancing and MMP production suppressing effects.

[0097] Human normal fibroblasts were cultured in 24-well plates at 3.0 × 10 cells in DMEM medium containing 10% FBS. 4 Cells / well were seeded and cultured overnight at 37℃ and 5% CO2. After culture, the medium was removed and replaced with DMEM medium (containing 1% FBS) containing or not containing 100ng of leontopodic acid A (or B), and cultured for another 48 hours. After culture, the cells were washed with PBS and collected, and RNA was extracted using QIAshredder, RNeasy Mini Kit (QIAGEN) and QIAcube (QIAGEN). The extracted RNA was converted to cDNA using SuperScript VILO cDNA Synthesis Kit (Invitrigen), and RT-qPCR was performed using SYBR (QIAGEN) and QuantStudio 7 (Applied Biosystems) to analyze the expression levels of the COL1A1 gene and MMP1 gene. The β-Actin gene was used as an endogenous control. The significance of differences between groups was tested using the student-T test. Leontopodic acids A and B were purchased from EXTRASYNTHESE. The results are shown in Table 1 and Figures 1 and 2.

[0098] [Table 1]

[0099] As shown in Table 1, FIG. 1 and FIG. 2, in normal human fibroblasts to which leontopodic acid A (or B) was added, the effects of enhancing type I collagen production and suppressing MMP-1 production were observed. From this, it was found that leontopodic acid and extracts containing leontopodic acid have the effect of enhancing the production of type I collagen and suppressing the production of MMP-1. It was also found that leontopodic acid and extracts containing leontopodic acid are likely to exhibit the effects of enhancing collagen production and inhibiting MMP production.

[0100] <Test Example 2> Selection of plant extracts with characteristics similar to those of leontopodine acid; HPLC analysis of mugwort extract, peach leaf extract, and amacha extract We selected plant extracts with characteristics similar to those of leontopodic acid used in the test examples described below. Using HPLC analysis, we selected mugwort extract, peach leaf extract, and amacha extract from among the candidate substances.

[0101] Then, HPLC analysis was performed on the mugwort extract, peach leaf extract, and amacha extract, and peaks (peaks 1 and 2) with spectra similar to those of leontopodic acid were detected. The results are shown in Table 2. -: No corresponding peak ○: Similar to leontopodine acid [HPLC conditions] Detector: Photodiode array detector (measurement wavelength: 330 nm, spectrum measurement range: 190 to 400 nm) Column: Unison UK C18 (3 μm, 3 mm × 10 cm) Mobile phase: Water+1%HCOOH72 / ACN28(v / v) Flow rate: 0.5mL / min Temperature: 40℃

[0102] [Table 2]

[0103] From these results, it is inferred that mugwort extract, peach leaf extract, and amacha extract have effects similar to those of leontopodine acid. The following evaluations were carried out on the mugwort extract, peach leaf extract and amacha extract.

[0104] <Test Example 3> Collagen production enhancement and MMP production inhibition test of mugwort extract, peach leaf extract, and amacha extract Next, the mugwort extract, peach leaf extract, and amacha extract selected in Test Example 2 were evaluated for their collagen production enhancing and MMP production inhibiting effects.

[0105] Human normal fibroblasts were cultured in 24-well plates at 3.0 × 10 cells in DMEM medium containing 10% FBS. 4 Cells / well were seeded and cultured overnight at 37℃ and 5% CO2. After culture, the medium was removed and replaced with DMEM medium (containing 1% FBS) containing 0.25% or 1% of the test extract, or without it, and cultured for another 48 hours. After culture, the cells were washed with PBS and collected, and RNA was extracted using QIAshredder, RNeasy Mini Kit (QIAGEN) and QIAcube (QIAGEN). The extracted RNA was converted to cDNA using SuperScript VILO cDNA Synthesis Kit (Invitrigen), and RT-qPCR was performed using SYBR (QIAGEN) and QuantStudio 7 (Applied Biosystems) to analyze the expression levels of the COL1A1 gene and MMP1 gene. The β-Actin gene was used as an endogenous control.

[0106] [Table 3]

[0107] As shown in Table 3, in normal human fibroblasts to which mugwort extract, peach leaf extract, and amacha extract were added, type I collagen production was enhanced and MMP-1 production was inhibited. This shows that mugwort extract, peach leaf extract, and amacha extract have the effect of enhancing type I collagen production and inhibiting MMP-1 production. It was also found that mugwort extract, peach leaf extract, and amacha extract may have the effect of promoting collagen production and inhibiting MMP production.

[0108] <Test Example 4> Impression evaluation regarding lifting Next, a sensory test was carried out to examine the effect of the topical skin composition of the present invention on skin lifting.

[0109] First, 1% peach leaf extract was mixed with an existing cosmetic preparation (cream) to obtain a skin external composition of the present invention.

[0110] The sensory test was conducted on 36 healthy Japanese women (aged 35-54) as subjects. The subjects applied the skin topical composition of the present invention to their faces twice a day, morning and night, for 12 weeks, and photographs of the subjects' faces before and after continuous use were evaluated by five expert panelists (2 men and 3 women, aged 30-50).

[0111] At this time, the photographs before and after continuous use were randomly and blindly presented to the expert panelists. The two photographs were evaluated for lifting sensation using a three-point scale of "no change", "slight change", and "change". After the evaluation by the expert panelists, the number of weeks for the photographs rated as "slight change" and "change" were confirmed, and the lifting sensation was evaluated according to the following criteria.

[0112] standard: 1) Change: Four or more out of five expert panelists rated the product as "changing" or "slightly changing" after use compared to before use. 2) Slight change: Three out of five expert panelists rated that they "felt a change" or "felt a slight change" after continued use compared to before continued use. 3) Slightly no change: Three out of five expert panelists rated the condition as "no change" after continued use compared to before continued use. 4) No change: Four or more of the five expert panelists rated the condition as "no change" after continuous use compared to before continuous use.

[0113] [Table 4]

[0114] As shown in Table 4, more than half (19 / 36) of the subjects rated that there was a "feeling of lifting" after continued use compared to before continued use (more than three out of five expert panelists rated that there was a "change" or "slight change"), demonstrating that the topical skin composition of the present invention has a lifting effect. In other words, it was found that peach leaf extract has a lifting effect. Combined with the results of Test Example 2, it can be said that leontopodic acid, mugwort extract, and amacha extract, which, like peach leaf extract, have the effect of enhancing type I collagen production and inhibiting MMP-1 production, also have a lifting effect.

[0115] <Test Example 5> Verification of skin properties that contribute to the evaluation of "lifted" Next, the skin properties that contribute to the evaluation of "lifted" were examined. Specifically, using data from subjects who were rated as "changed" or "no change" in the impression evaluation results (hereinafter referred to as the "changed" and "no change" groups), skin physical properties that showed significant differences between the two groups were extracted and these skin physical properties were verified.

[0116] As a result, it was found that the skin property known as "lifted feeling" has one or more of the following characteristics. (Features) -Improved symmetry of cheek volume - Reduces anisotropy of cheek skin surface morphology -Before and after continuous use, the skin surface shifts from the center of the face outwards and upwards

[0117] The above features will be described in detail below using test examples.

[0118] <Test Example 5-1> Symmetry of cheek volume Using VECTRA (Canfield Scientific), the left and right cheek volume of the "changed" and "no change" groups was measured. In measuring cheek volume, the software installed in VECTRA was used to calculate the change in cheek volume before and after continuous use. The difference between the left and right sides of the calculated cheek volume change was then calculated. The results are shown in Figure 3. The vertical axis of the graph in the figure shows the magnitude of the difference between the left and right cheek volume change before and after continuous use.

[0119] As shown in Figure 3, the difference in cheek volume change between the left and right sides in the "changed" group was smaller than in the "no change" group. This shows that the action of achieving a lift-up effect includes improving the symmetry of cheek volume between the left and right sides.

[0120] Additionally, in the image sample in which the sense of volume was increased on only one cheek, the degree of "lifting" was rated as low. In other words, it was found that the lifting of the upper cheek itself does not contribute to the evaluation of "lifting," but that the improvement in the symmetry of the sense of volume on the left and right cheeks contributes to the skin property of "lifting."

[0121] <Test Example 5-2> Anisotropy of cheek skin surface morphology In the impression evaluation, the cheek skin surface morphology was measured for the "changed" and "no change" groups. Specifically, the cheek skin surface was measured using PRIMOS_CR_LargeField (Canfield Scientific), and the anisotropy data of the cheek skin surface was obtained using the attached software. The results are shown in Figures 4 and 5. The vertical axis of Figure 4 shows the measured anisotropy value, and the vertical axis of Figure 5 shows the change in anisotropy before and after continuous use for each of the "changed" and "no change" groups.

[0122] As shown in Figure 4, it can be seen that the anisotropy of the cheek skin surface of more than half of the subjects in the "changed" group decreased before and after continuous use. Also, as shown in Figure 5, it can be seen that the degree of decrease in anisotropy of the "changed" group before and after continuous use was greater than the degree of decrease in anisotropy of the "no change" group. From this, it can be seen that the action for achieving a lifting effect includes a decrease in the anisotropy of the cheek skin surface morphology.

[0123] <Test Example 5-3> Movement pattern of cheek skin surface The movement patterns of the cheek skin surface were measured for the "changed" and "no change" groups in the impression evaluation. Specifically, facial photographs of the subjects before and after continuous use were taken using a VECTRA M3 (Canfield Scientific), and the amount of skin movement before and after continuous use was calculated. The amount of movement of the skin was calculated using optical flow analysis in MATLAB (registered trademark) (manufactured by MathWorks, Inc.). Specifically, the position information of feature points (e.g., moles, blemishes, pores) in the facial image data before continuous use was compared with the position information of feature points (e.g., moles, blemishes, pores) in the facial image data after continuous use, and the amount of change over time was obtained based on the comparison results, thereby measuring the amount of skin movement from the facial image data. The amount of skin movement includes the distance and direction of skin movement, and the amount of skin movement is indicated by an arrow on the facial photograph. Of the amount of skin movement, we focused on the amount of skin movement in the lower cheek area and counted the number of arrows pointing outward and upward from the center of the face. The results are shown in Figure 6. The vertical axis of the graph shows the number of arrows that have moved outward and upward from the center of the face per unit area of ​​skin, as obtained by optical flow analysis.

[0124] As shown in Figure 6, the number of arrows pointing outward and upward in the lower cheek area of ​​the "changed" group was greater than that of the "no change" group. This shows that the action required to achieve a lifting effect involves the skin surface of the lower cheek moving outward and upward.

[0125] Test Examples 5-1 to 5-3 revealed that the actions required to achieve a lift-up effect include one or more of the following: improving the left-right symmetry of cheek volume, reducing the anisotropy of the cheek skin surface morphology, and shifting the skin surface outward and upward from the center of the face.

[0126] In other words, from the results of Test Examples 4 and 5-1 to 5-3, it was found that leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloideae in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae have a lifting effect (improving the symmetry of the cheek volume, reducing the anisotropy of the cheek skin surface morphology, and exerting the effect of moving the skin surface outward and upward from the center of the face).

[0127] Moreover, the results of Test Examples 1 to 4 and Test Examples 5-1 to 5-3 demonstrated that the above-mentioned active ingredients have a face-lifting effect.

[0128] Additionally, changes in the three-dimensional shape of the face, such as a drooping appearance of the face, can give the impression of aging. Here, the results of Test Examples 1 to 4 and Test Examples 5-1 to 5-3 show that the above-mentioned active ingredients have a lifting effect and a face-lifting effect. In other words, it was found that the above-mentioned active ingredients have an effect of preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face. [Industrial Applicability]

[0129] According to the present invention, a composition capable of enhancing collagen production and suppressing MMP production can be provided.

Claims

1. An agent for enhancing collagen production and inhibiting MMP (matrix metalloproteinase) production, comprising as an active ingredient one or more selected from the group consisting of leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloidea of ​​the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae.

2. The collagen is type I collagen, 2. The collagen production enhancing and MMP (matrix metalloprotease) production inhibitor according to claim 1, wherein the MMP (matrix metalloprotease) is MMP-1.

3. A collagen production enhancer and MMP (matrix metalloproteinase) production inhibitor as described in claim 1 or 2 for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face.

4. A collagen production enhancer and MMP (matrix metalloproteinase) production inhibitor according to claim 1 or 2, for lifting the skin.

5. A collagen production enhancer and MMP (matrix metalloproteinase) production inhibitor according to claim 1 or 2 for lifting the skin.

6. The collagen production enhancer and MMP (matrix metalloproteinase) production inhibitor according to claim 1 or 2, wherein the plant extract is one or more selected from mugwort extract, peach leaf extract and amacha extract.

7. The collagen production enhancer and MMP (matrix metalloproteinase) production inhibitor according to claim 1 or 2, wherein the leontopodic acid is leontopodic acid A and / or leontopodic acid B.

8. A skin topical composition for enhancing collagen production and inhibiting MMP (matrix metalloproteinase) production, comprising as an active ingredient one or more selected from leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia in the family Asteraceae, the genus Amygdaloidea in the family Rosaceae, and the genus Hydrangea in the family Saxifragaceae.

9. The composition for external application to skin according to claim 8, which is a cosmetic preparation.

10. The composition for external application to the skin according to claim 8 , which is applied under the same conditions to both the left and right cheeks.

11. A skin external composition for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face, comprising one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloidea of ​​the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae.

12. A skin lifting agent comprising, as an active ingredient, one or more selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloidea of ​​the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae.

13. A skin external composition for lifting the skin, comprising as an active ingredient one or more selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloidea of ​​the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae.

14. A skin external composition for lifting the skin, comprising as an active ingredient one or more selected from leontopodic acid, an extract containing leontopodic acid, and one or more plant extracts of plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloidea of ​​the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae.

15. A method for preventing or improving the impression of aging caused by changes in the three-dimensional shape of the face (excluding medical procedures), comprising applying to the left and right cheeks under the same conditions a skin external composition containing one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloidea of ​​the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae.

16. A method for lifting the skin (excluding medical procedures) includes applying a skin topical composition containing one or more active ingredients selected from leontopodic acid, an extract containing leontopodic acid, and a plant extract of one or more plants belonging to the genus Astemisia of the family Asteraceae, the genus Amygdaloidea of ​​the family Rosaceae, and the genus Hydrangea of ​​the family Saxifragaceae to both the left and right cheeks under the same conditions.

Citation Information

Patent Citations

  • Collagenase inhibitor and skin lotion for senescence prevention containing the same

    JP1998194982A

  • Antiaging agent

    JP1999335235A

  • Active oxygen-eliminating agent and skin cosmetic for preventing aging

    JP2001288032A

  • Anti-aging agent, and skin care preparation, foodstuff and beverage

    JP2009242263A

  • Type iv collagen production promoter

    JP2009298723A